Atherogenesis in Native Coronary Segments and In-Stent Neoatherogenesis Beyond Three Years After First-Generation Drug-Eluting Stent Implantation: Angiographic and Optical Coherence Tomography Study

1. Otsuka F, Byrne RA, Yahagi K, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015;36:2147-2159.

2. Adriaenssens T, Joner M, Godschalk TC, et al. Optical coherence tomography findings in patients with coronary stent thrombosis: a report of the PRESTIGE consortium (prevention of late stent thrombosis by an interdisciplinary global European effort). Circulation. 2017;136:1007-1021.

3. Lee SY, Hur SH, Lee SG, et al. Optical coherence tomographic observation of in-stent neoatherosclerosis in lesions with more than 50% neointimal area stenosis after second-generation drug-eluting stent implantation. Circ Cardiovasc Interv. 2015;8:001878.

4. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57:1314-1322.

5. Ali ZA, Roleder T, Narula J, et al. Increased thin-cap neoatheroma and periprocedural myocardial infarction in drug-eluting stent restenosis: multimodality intravascular imaging of drug-eluting and bare-metal stents. Circ Cardiovasc Interv. 2013;6:507-517.

6. Joner M, Koppara T, Byrne RA, et al. Neoatherosclerosis in patients with coronary stent thrombosis: findings from optical coherence tomography imaging (a report of the PRESTIGE Consortium). JACC Cardiovasc Interv. 2018;11:1340-1350.

7. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333-342.

8. Otsuka F, Finn AV, Yazdani SK, Nakano M, Kolodgie FD, Virmani R. The importance of the endothelium in atherothrombosis and coronary stenting. Nat Rev Cardiol. 2012;9:439-453.

9. Otsuka F, Vorpahl M, Nakano M, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014;129:211-223.

10. Tomaniak M, Kołtowski Ł, Pietrasik A, et al. A serial 3- and 9-year optical coherence tomography assessment of vascular healing response to sirolimus- and paclitaxel-eluting stents. Int J Cardiovasc Imaging. 2019;35:9-21.

11. Tomaniak M, Kochman J, Koltowski L, et al. A serial three- and nine-year optical coherence tomography evaluation of neoatherosclerosis progression after sirolimus- and paclitaxel-eluting stent implantation. Kardiol Pol. 2018;76:1251-1256.

12. Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975;51:5-40.

13. Paoletti G, Gomez-Lara J, Brugaletta S, et al. Association between coronary atherosclerosis progression and in-stent neoatherosclerosis in patients with ST-elevation myocardial infarction at five-year follow-up. EuroIntervention. 2018;14:206-214.

14. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100:1872-1878.

15. Prati F, Guagliumi G, Mintz GS, et al. Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. Eur Heart J. 2012;33:2513-2520.

16. Borovac JA, D'Amario D, Vergallo R, et al. Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challenge. Eur Heart J Cardiovasc Pharmacother. 2019;5:105-116.

17. Tearney GJ, Regar E, Akasaka T, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol. 2012;59:1058-1072.

18. Lutter C, Mori H, Yahagi K, et al. Histopathological differential diagnosis of optical coherence tomographic image interpretation after stenting. JACC Cardiovasc Interv. 2016;9:2511-2523.

19. Ochijewicz D, Tomaniak M, Koltowski L, et al. Peri-strut low intensity areas and in-scaffold neointima growth after bioresorbable scaffold implantation in STEMI. A serial optical coherence tomography study. Int J Cardiol. 2020;18:35347-35341.

20. Kuroda M, Otake H, Shinke T, et al. The impact of in-stent neoatherosclerosis on long-term clinical outcomes: an observational study from the Kobe University Hospital optical coherence tomography registry. EuroIntervention. 2016;12:e1366-e1374.

21. Yonetsu T, Kato K, Kim SJ, et al. Predictors for neoatherosclerosis: a retrospective observational study from the optical coherence tomography registry. Circ Cardiovasc Imaging. 2012;5:660-666.

22. Yahagi K, Kolodgie FD, Otsuka F, et al. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat Rev Cardiol. 2016;13:79-98.

23. Nakazawa G, Finn AV, Vorpahl M, et al. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol. 2011;57:390-398.

24. Cook S, Ladich E, Nakazawa G, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009;120:391-399.

25. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407-477.

26. Kuroda K, Otake H, Shinke T, et al. Peri-strut low-intensity area assessed by midterm follow-up optical coherence tomography may predict target lesion revascularisation after everolimus-eluting stent implantation. EuroIntervention. 2019;14:1751-1759.

27. Prati F, Gatto L, Romagnoli E, et al. In vivo vulnerability grading system of plaques causing acute coronary syndromes: an intravascular imaging study. Int J Cardiol. 2018;269:350-355.

28. Usui E, Yonetsu T, Kanaji Y, et al. Prevalence of neoatherosclerosis in sirolimus-eluting stents in a very late phase after implantation. EuroIntervention. 2018;14:e1316-e1323.

29. Taniwaki M, Windecker S, Zaugg S, et al. The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study. Eur Heart J. 2015;36:2167-2176.

30. Moriyama N, Shishido K, Tanaka Y, et al. Neoatherosclerosis 5 years after bioresorbable vascular scaffold implantation. J Am Coll Cardiol. 2018;71:1882-1893.

31. Harari E, Guo L, Smith SL, et al. Direct targeting of the mTOR (mammalian target of rapamycin) kinase improves endothelial permeability in drug-eluting stents-brief report. Arterioscler Thromb Vasc Biol. 2018;38:2217-2224.

32. Wilson GJ, McGregor J, Conditt G, et al. Impact of bioresorbable versus permanent polymer on longterm vessel wall inflammation and healing: a comparative drug-eluting stent experimental study. EuroIntervention. 2018;13:1670-1679.

33. Iglesias JF, Muller O, Heg D, et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet. 2019;394:1243-1253.

34. Kereiakes DJ, Windecker S, Jobe RL, et al. Clinical outcomes following implantation of thin-strut, bioabsorbable polymer-coated, everolimus-eluting SYNERGY stents. Circ Cardiovasc Interv. 2019;12:27.

35. Picard F, Pighi M, de Hemptinne Q, et al. Comparison of the biodegradable polymer everolimus-eluting stent with contemporary drug-eluting stents: a systematic review and meta-analysis. Int J Cardiol. 2019;278:51-56.

36. Phipps JE, Vela D, Hoyt T, et al. Macrophages and intravascular OCT bright spots: a quantitative study. JACC Cardiovasc Imaging. 2015;8:63-72.